Review of synthesis, assay, and prediction of β and γ-secretase inhibitors

Current Topics in Medicinal Chemistry

Volumn 12, Issue 8, 2012, Pages 828-844

  Niño, Helena ^a   Rodríguez Borges, José Enrique ^b   García Mera, Xerardo ^a   Prado Prado, Francisco ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

secretase inhibitors; secetase inhibitors; Alzheimer's disease (AD); COMFA; CoMSIA; Docking; QSAR

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; BETA SECRETASE INHIBITOR; GAMMA SECRETASE INHIBITOR; HYDANTOIN DERIVATIVE; MACROCYCLIC COMPOUND; PRESENILIN 1; PRESENILIN 2; PYRIDINIUM DERIVATIVE; STATINE DERIVATIVE;

ALZHEIMER DISEASE; ARTIFICIAL NEURAL NETWORK; AUTOSOMAL DOMINANT INHERITANCE; COGNITIVE DEFECT; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DEMENTIA; DRUG DESIGN; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; FAMILIAL DISEASE; GENE MUTATION; HUMAN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; NEUROPATHOLOGY; NONHUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SENILE PLAQUE;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860270472     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612800166774     Document Type: Review

References (97)

1. Golde, T.E.; Dickson, D.; Hutton, M. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Curr. Alzheimer. Res., 2006, 3(5), 421-430.
2. Hutton M, Perez-Tur J, Hardy J. Genetics of Alzheimer's disease. Essays Biochem., 1998, 33, 117-131.
3. Younkin, S.G. The role of A beta 42 in Alzheimer's disease. J. Physiol. Paris, 1998, 92(3-4), 289-92.
4. Sisodia, S.S. Alzheimer's disease: perspectives for the new millennium. J. Clin. Invest., 1999, 104(9), 1169-1170.
5. Rovelet-Lecrux, A.; Hannequin, D.; Raux, G.; Le Meur, N.; Laquerriere, A.; Vital, A.; Dumanchin, C.; Feuillette, S.; Brice, A.; Vercelletto, M.; Dubas, F.; Frebourg, T.; Campion, D. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat. Genet., 2006, 38(1), 24-26.
6. Ohno, M.; Sametsky, E. A; Younkin, L.H.; Oakley, H.; Younkin, S.G.; Citron, M.; Vassar, R.; Disterhoft, J.F. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron, 2004, 41(1), 27-33.
7. Ohno, M.; Cole, S.L.; Yasvoina, M.; Zhao, J.; Citron, M.; Berry, R.; Disterhoft, J.F.; Vassar, R. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiol. Dis., 2007, 26(1), 134-145.
8. Laird, F.M.; Cai, H.; Savonenko, A.V.; Farah, M.H.; He, K.; Melnikova, T.; Wen, H.; Chiang, H.C.; Xu, G.; Koliatsos, V.E.; Borchelt, D.R.; Price, D.L.; Lee, H.K.; Wong, P.C. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci., 2005, 25(50), 11693-11709.
9. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81(2), 741-766.
10. Vassar R. BACE1: The beta-secretase enzyme in Alzheimer's disease. J. Mol. Neurosci., 2004, 23(1-2), 105-114.
11. Hussain, I.; Powell, D.; Howlett, D.R.; Tew, D.G.; Meek, T.D.; Chapman, C.; Gloger, I.S.; Murphy, K.E.; Southan, C.D.; Ryan, D.M.; Smith, T.S.; Simmons, D.L.; Walsh, F.S.; Dingwall, C.; Christie, G. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell Neurosci., 1999, 14(6), 419-427.
12. Sinha, S.; Anderson, J.P.; Barbour, R.; Basi, G.S.; Caccavello, R.; Davis, D.; Doan, M.; Dovey, H.F.; Frigon, N.; Hong, J.; Jacobson-Croak, K.; Jewett, N.; Keim, P.; Knops, J.; Lieberburg, I.; Power, M.; Tan, H.; Tatsuno, G.; Tung, J.; Schenk, D.; Seubert, P.; Suomensaari, S.M.; Wang, S.; Walker, D.; Zhao, J.; McConlogue, L.; John, V. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature, 1999, 402(6761), 537-540.
13. Vassar, R.; Bennett, B.D.; Babu-Khan, S.; Kahn, S; Mendiaz, E.A.; Denis, P.; Teplow, D.B.; Ross, S.; Amarante, P.; Loeloff, R.; Luo, Y.; Fisher, S.; Fuller, J.; Edenson, S.; Lile, J.; Jarosinski, M.A.; Biere, A.L.; Curran, E.; Burgess, T.; Louis, J.C.; Collins, F.; Treanor, J.; Rogers, G.; Citron, M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 1999, 286(5440), 735-741.
14. Yan, R.; Bienkowski, M.J.; Shuck, M.E.; Miao, H.; Tory, M.C.; Pauley, A.M.; Brashier, J.R.; Stratman, N.C.; Mathews, W.R.; Buhl, A.E.; Carter, D.B.; Tomasselli, A.G.; Parodi, L.A.; Heinrikson, R.L.; Gurney, M.E. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature, 1999, 402(6761), 533-537.
15. Goate, A.; Chartier-Harlin, M.C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 1991, 349(6311), 704-706.
16. Schellenberg, G.D.; Bird, T.D.; Wijsman, E.M.; Orr, H.T; Anderson, L.; Nemens, E.; White, J.A.; Bonnycastle, L.; Weber, J.L.; Alonso, M.E. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science, 1992, 258(5082), 668-671.
17. Haass, C.; Schlossmacher, M.G.; Hung, A.Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B.L.; Lieberburg, I.; Koo, E.H.; Schenk, D.; Teplow, D.B. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature, 1992, 359(6393), 322-325.
18. Seubert, P.; Oltersdorf, T.; Lee, M.G.; Barbour, R.; Blomquist, C.; Davis, DL.; Bryant, K.; Fritz, L.C.; Galasko, D.; Thal, L.J. Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide. Nature, 1993, 361(6409), 260-263.
19. Zhao, J.; Paganini, L.; Mucke, L.; Gordon, M.; Refolo, L.; Carman, M.; Sinha, S.; Oltersdorf, T.; Lieberburg, I.; McConlogue, L. Betasecretase processing of the beta-amyloid precursor protein in transgenic mice is efficient in neurons but inefficient in astrocytes. J. Biol. Chem., 1996, 271(49), 31407-31411.
20. Citron, M.; Teplow, D.B.; Selkoe, D.J. Generation of amyloid beta protein from its precursor is sequence specific. Neuron, 1995, 14(3), 661-670.
21. Santana, L.; Uriarte, E.; González-Díaz, H.; Zagotto, G.; Soto-Otero, R.; Mendez-Alvarez, E. A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J. Med. Chem., 2006, 49(3), 1149-1156.
22. Marrero-Ponce, Y. Linear indices of the molecular pseudograph's atom adjacency matrix: definition, significance-interpretation, and application to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. J. Chem. Inf. Comput. Sci., 2004, 44(6), 2010-2026.
23. Vilar, S.; Santana, L.; Uriarte, E. Probabilistic neural network model for the in silico evaluation of anti-HIV activity and mechanism of action. J. Med. Chem., 2006, 49(3), 1118-1124.
24. Marrero-Ponce, Y.; Khan, M.T.; Casanola Martin, G.M.; Ather, A.; Sultankhodzhaev, M.N.; Torrens, F.; Rotondo, R. Prediction of Tyrosinase Inhibition Activity Using Atom-Based Bilinear Indices. Chem Med Chem, 2007, 2(4), 449-478.
25. Casanola-Martin, G.M.; Marrero-Ponce, Y.; Khan, M.T.; Ather, A.; Sultan, S.; Torrens, F.; Rotondo, R. TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-based linear indices. Bioorg. Med. Chem., 2007, 15(3), 1483-1503.
26. Casanola-Martin, G.M.; Marrero-Ponce, Y.; Khan, M.T.; Ather, A.; Khan, K.M.; Torrens, F.; Rotondo, R. Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays. Eur. J. Med. Chem., 2007, 42(11-12), 1370-1381.
27. Caballero, J.; Fernandez, M. Artificial neural networks from MATLAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN), application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1). Curr. Top. Med. Chem., 2008, 8(18), 1580-1605.
28. Duardo-Sanchez, A.; Patlewicz, G.; Lopez-Diaz, A. Current topics on software use in medicinal chemistry: intellectual property, taxes, and regulatory issues. Curr. Top. Med. Chem., 2008, 8(18), 1666-1675.
29. Gonzalez, M.P.; Teran, C.; Saiz-Urra, L.; Teijeira, M. Variable selection methods in QSAR: an overview. Curr. Top. Med. Chem., 2008, 8(18), 1606-1627.
30. Gonzalez-Diaz, H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr. Top. Med. Chem., 2008, 8(18), 1554.
31. Gonzalez-Diaz, H.; Prado-Prado, F.; Ubeira, F.M. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr. Top. Med. Chem., 2008, 8(18), 1676-1690.
32. Helguera, A.M.; Combes, R.D.; Gonzalez, M.P.; Cordeiro, M.N. Applications of 2D descriptors in drug design: a DRAGON tale. Curr. Top. Med. Chem., 2008, 8(18), 1628-1655.
33. Ivanciuc, O. Weka machine learning for predicting the phospholipidosis inducing potential. Curr. Top. Med. Chem., 2008, 8(18), 1691-1709.
34. Vilar, S.; Cozza, G.; Moro, S. Medicinal chemistry and the molecular operating environment (MOE), application of QSAR and molecular docking to drug discovery. Curr. Top. Med. Chem., 2008, 8(18), 1555-1572.
35. Wang, J.F.; Wei, D.Q.; Chou, K.C. Drug candidates from traditional chinese medicines. Curr. Top. Med. Chem., 2008, 8(18), 1656-1665.
36. Wang, J.F.; Wei, D.Q.; Chou, K.C. Pharmacogenomics and personalized use of drugs. Curr. Top. Med. Chem., 2008, 8(18), 1573-1579.
37. Chen, J.; Shen, B. Computational Analysis of Amino Acid Mutation: a Proteome Wide Perspective. Curr. Proteom., 2009, 6(4), 228-234.
38. Chou, K.C. Pseudo amino acid composition and its applications in bioinformatics, proteomics and system biology. Curr. Proteom., 2009, 6(4), 262-274.
39. Giuliani A, Di Paola L, Setola R. Proteins as Networks: A mesoscopic approach using haemoglobin molecule as case study. Curr. Proteom., 2009, 6(4), 235-245.
40. González-Díaz, H.; Prado-Prado, F.; Pérez-Montoto, L.G.; Duardo-Sánchez, A.; López-Díaz, A. QSAR models for proteins of parasitic organisms, plants and human guests: Theory, applications, legal protection, Taxes, and regulatory issues. Curr. Proteom., 2009, 6, 214-227.
41. Ivanciuc O. Machine learning quantitative structure-activity relationships (QSAR) for peptides binding to human amphiphysin-1 SH3 domain. Curr. Proteom., 2009, 4(6), 289-302.
42. Pérez-Montoto, L.G.; Prado-Prado, F.; Ubeira, F.M.; González-Díaz, H. Study of parasitic infections, cancer, and other diseases with mass-spectrometry and quantitative proteome-disease relationships. Curr. Proteom., 2009, 6, 246-261.
43. Torrens, F.; Castellano, G. Topological charge-transfer indices: from small molecules to proteins. Curr. Proteom., 2009, 6(4), 204-213.
44. Vázquez, J.M.; Aguiar, V.; Seoane, J.A.; Freire, A.; Serantes, J.A.; Dorado, J.; Pazos, A.; Munteanu, C.R. Star Graphs of Protein Sequences and Proteome Mass Spectra in Cancer Prediction. Curr. Proteom., 2009, 6(4), 275-288.
45. Chou, K.C. Graphic rule for drug metabolism systems. Curr. Drug Metab., 2010, 11(4), 369-378.
46. Garcia, I.; Diop, Y.F.; Gomez, G. QSAR & complex network study of the HMGR inhibitors structural diversity. Curr. Drug. Metab., 2010, 11(4), 307-314.
47. Gonzalez-Diaz, H. Network topological indices, drug metabolism, and distribution. Curr. Drug Metab., 2010, 11(4), 283-284.
48. Gonzalez-Diaz, H.; Duardo-Sanchez, A.; Ubeira, F.M.; Prado-Prado, F.; Perez-Montoto, L.G.; Concu, R.; Podda, G.; Shen, B. Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr. Drug Metab., 2010, 11(4), 379-406.
49. Khan, M.T. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Curr. Drug Metab., 2010, 11(4), 285-295.
50. Martinez-Romero, M.; Vazquez-Naya, J.M.; Rabunal, J.R.; Pita-Fernandez, S.; Macenlle, R.; Castro-Alvarino, J.; Lopez-Roses, L.; Ulla, J.L.; Martinez-Calvo, A.V.; Vazquez, S.; Pereira, J.; Porto-Pazos, A.B.; Dorado, J.; Pazos, A.; Munteanu, C.R. Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network. Curr. Drug Metab., 2010, 11(4), 347-368.
51. Mrabet, Y.; Semmar, N. Mathematical methods to analysis of topology, functional variability and evolution of metabolic systems based on different decomposition concepts. Curr. Drug Metab., 2010, 11(4), 315-341.
52. Wang, J.F.; Chou, K.C. Molecular modeling of cytochrome P450 and drug metabolism. Curr. Drug Metab., 2010, 11(4), 342-346.
53. Zhong, W.Z.; Zhan, J.; Kang, P.; Yamazaki, S. Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation. Curr. Drug Metab., 2010, 11(4), 296-306.
54. Concu, R.; Podda, G.; Ubeira, F.M.; Gonzalez-Diaz, H. Review of QSAR models for enzyme classes of drug targets: theoretical background and applications in parasites, hosts, and other organisms. Curr. Pharm. Des., 2010, 16(24), 2710-2723.
55. Estrada, E.; Molina, E.; Nodarse, D.; Uriarte, E. Structural contributions of substrates to their binding to P-Glycoprotein. A TOPS-MODE approach. Curr. Pharm. Des., 2010, 16(24), 2676-2709.
56. Garcia, I.; Fall, Y.; Gomez, G. QSAR, Docking, and CoMFA Studies of GSK3 Inhibitors. Curr. Pharm. Des., 2010, 16(24), 2666-2675.
57. Prado-Prado, F.J.; Garcia-Mera, X.; Gonzalez-Diaz, H. Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorg. Med. Chem., 2010, 18(6), 2225-2231.
58. Marrero-Ponce, Y.; Casanola-Martin, G.M.; Khan, M.T.; Torrens, F.; Rescigno, A.; Abad, C. Ligand-Based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMDCARDD method to the elucidation of new compounds. Curr. Pharm. Des., 2010,16(24), 2601-2624.
59. Munteanu, C.R.; Fernandez-Blanco, E.; Seoane, J.A.; Izquierdo-Novo, P.; Rodriguez-Fernandez, J.A.; Prieto-Gonzalez, J.M.; Rabunal, J.R.; Pazos, A. Drug discovery and design for complex diseases through QSAR computational methods. Curr. Pharm. Des., 2010, 16(24), 2640-2655.
60. Roy, K.; Ghosh, G. Exploring QSARs with extended topochemical atom (ETA) indices for modeling chemical and drug toxicity. Curr. Pharm. Des., 2010, 16(24), 2625-2639.
61. Speck-Planche, A.; Scotti, M.T.; de Paulo-Emerenciano, V. Current pharmaceutical design of antituberculosis drugs: future perspectives. Curr. Pharm. Des., 2010, 16(24), 2656-2665.
62. Vazquez-Naya, J.M.; Martinez-Romero, M.; Porto-Pazos, A.B.; Novoa, F.; Valladares-Ayerbes, M.; Pereira, J.; Munteanu, C.R.; Dorado, J. Ontologies of drug discovery and design for neurology, cardiology and oncology. Curr. Pharm. Des., 2010, 16(24), 2724-2736.
63. Chiş, O.; Dumitru, O.; Concu, R.; Shen, B. Reviewing Yeast Network and report of new Stochastic-Credibility cell cycle models. Curr. Bioinform., 2011, 6(1), 35-43.
64. Dave, K.; Banerjee, A. Bioinformatics analysis of functional relations between CNPs regions. Curr. Bioinform., 2011, 6(1), 122-128.
65. Duardo-Sanchez, A.; Patlewicz, G.; González-Díaz, H. A Review of network topological indices from chem-bioinformatics to legal sciences and back. Curr. Bioinform., 2011, 6(11), 53-70.
66. García, I.; Fall, Y.; Gómez, G. Trends in Bioinformatics and Chemoinformatics of Vitamin D analogues and their protein targets. Curr. Bioinform., 2011, 6(1), 16-24.
67. Ivanciuc, T.; Ivanciuc, O.; Klein, D.J. Network-QSAR with reaction poset quantitative superstructure-activity relationships (QSSAR) for PCB Chromatographic properties. Curr. Bioinform., 2011, 6(1), 25-34.
68. Prado-Prado, F.; Escobar-Cubiella, M.; García-Mera, X. Review of Bioinformatics and QSAR studies of β-secretase inhibitors. Curr. Bioinform., 2011, 6(1), 3-15.
69. Riera-Fernández, P.; Munteanu, C.R.; Pedreira-Souto, N.; Duardo-Sanchez, A.; González-Díaz, H. Definition of Markov-harary invariants and review of classic topological indices and databases of biology, parasitology, technology, and social-legal networks. Curr. Bioinform. 2011, 6(1), 94-121.
70. Speck-Planche, A.; Cordeiro, M. Application of Bioinformatics for the search of novel anti-viral therapies: Rational design of antiherpes agents. Curr. Bioinform., 2011, 6(1), 81-93.
71. Wan, S.B.; Hu, L.L.; Niu, S.; Wang, K.; Cai, Y.D.; Lu, W.C.; Chou, K.C. Identification of multiple subcellular locations for proteins in budding yeast. Curr. Bioinform., 2011, 6(1), 71-80.
72. Bhattacharjee, B.; Jayadeepa, R.M.; Banerjee, S.; Joshi, J.; Middha, S.K.; Mole, J.P.; Samuel, J. Review of complex network and gene ontology in pharmacology approaches: mapping natural compounds on potential drug target colon cancer network. Curr. Bioinform., 2011, 6(1), 44-52.
73. Choi, S.J.; Cho, J.H.; Im, I.; Lee, S.D.; Jang, J.Y.; Oh, Y.M.; Jung, Y.K.; Jeon, E.S.; Kim, Y.C. Design and synthesis of 1,4-dihydropyridine derivatives as BACE-1 inhibitors. Eur. J. Med. Chem., 2010, 45(6), 2578-2590.
74. Yi Mok, N.; Chadwick, J.; Kellett, K.A.; Hooper, N.M.; Johnson, A.P.; Fishwick, C.W. Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. Bioorg. Med. Chem. Lett., 2009, 19(23), 6770-6774.
75. Sato, T.; Ananda, K.; Cheng, C.I.; Suh, E.J.; Narayanan, S.; Wolfe, M.S. Distinct pharmacological effects of inhibitors of signal peptide peptidase and gamma-secretase. J. Biol. Chem., 2008, 283(48), 33287-33295.
76. Sammi, T.; Silakari, O.; Ravikumar, M. Three-dimensional quantitative structure-activity relationship (3D-QSAR) studies of various benzodiazepine analogues of gamma-secretase inhibitors. J. Mol. Model., 2009, 15(4), 343-348.
77. Chakrabarti, E.; Ghosh, S.; Sadhukhan, S.; Sayre, L.; Tochtrop, G.P.; Smith, J.D. Synthesis and biological evaluation of analogues of a novel inhibitor of beta-amyloid secretion. J. Med. Chem., 2010, 53(14), 5302-5319.
78. Malamas, M.S.; Erdei, J.; Gunawan, I.; Turner, J.; Hu, Y.; Wagner, E.; Fan, K.; Chopra, R.; Olland, A.; Bard, J.; Jacobsen, S.; Magolda, R.L.; Pangalos, M.; Robichaud, A.J. Design and synthesis of 5,5'-disubstituted aminohydantoins as potent and selective human beta-secretase (BACE1) inhibitors. J. Med. Chem., 2010, 53(3), 1146-1158.
79. Back, M.; Nyhlen, J.; Kvarnstrom, I.; Appelgren, S.; Borkakoti, N.; Jansson, K.; Lindberg, J.; Nystrom, S.; Hallberg, A.; Rosenquist, S.; Samuelsson, B. Design, synthesis and SAR of potent statinebased BACE-1 inhibitors: exploration of P1 phenoxy and benzyloxy residues. Bioorg. Med. Chem., 2008, 16(21), 9471-9486.
80. Lindsley, S.R.; Moore, K.P.; Rajapakse, H.A; Selnick, H.G.; Young, M.B.; Zhu, H.; Munshi, S.; Kuo, L.; McGaughey, G.B.; Colussi, D.; Crouthamel, M.C.; Lai, M.T.; Pietrak, B.; Price, E.A.; Sankaranarayanan, S.; Simon, A.J.; Seabrook, G.R.; Hazuda, D.J.; Pudvah, N.T.; Hochman, J.H.; Graham, S.L.; Vacca, J.P.; Nantermet, P.G. Design, synthesis, and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(14), 4057-4061.
81. Stachel, S.J.; Coburn, C.A.; Steele, T.G.; Crouthamel, M.C.; Pietrak, B.L.; Lai, M.T.; Holloway, M.K.; Munshi, S.K.; Graham, S.L.; Vacca, J.P. Conformationally biased P3 amide replacements of beta-secretase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(3), 641-644.
82. Al-Nadaf, A.; Abu Sheikha, G.; Taha, M.O. Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads. Bioorg. Med. Chem., 2010, 18(9), 3088-3115.
83. Pandey, A.; Mungalpara, J.; Mohan, C.G. Comparative molecular field analysis and comparative molecular similarity indices analysis of hydroxyethylamine derivatives as selective human BACE-1 inhibitor. Mol. Divers, 2010, 14(1), 39-49.
84. Polgar, T.; Keseru, G.M. Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. J. Med. Chem., 2005, 48(11), 3749-3755.
85. Hetenyi, C.; Paragi, G.; Maran, U.; Timar, Z.; Karelson, M.; Penke, B. Combination of a modified scoring function with twodimensional descriptors for calculation of binding affinities of bulky, flexible ligands to proteins. J. Am. Chem. Soc., 2006, 128(4), 1233-1239.
86. Moitessier, N.; Therrien, E.; Hanessian, S. A method for inducedfit docking, scoring, and ranking of flexible ligands. Application to peptidic and pseudopeptidic beta-secretase (BACE 1) inhibitors. J. Med. Chem., 2006, 49(20), 5885-5894.
87. Salmon, S.A.; Watts, J.L. Minimum inhibitory concentration determinations for various antimicrobial agents against 1570 bacterial isolates from turkey poults. Avian. Dis., 2000, 44(1), 85-98.
88. Chou, K.C. Review: Structural bioinformatics and its impact to biomedical science. Curr. Med. Chem., 2004,11, 2105-2134.
89. Chou, K.C.; Wei, D. Q.; Du, Q. S.; Sirois, S.; Zhong, W. Z. Review: Progress in computational approach to drug development against SARS. Curr. Med. Chem., 2006, 13, 3263-3270.
90. Prado-Prado, F.J.; Gonzalez-Diaz, H.; de la Vega, O.M.; Ubeira, F.M.; Chou, K.C. Unified QSAR approach to antimicrobials. Part 3: first multi-tasking QSAR model for input-coded prediction, structural back-projection, and complex networks clustering of antiprotozoal compounds. Bioorg. Med. Chem., 2008, 16(11), 5871-5880.
91. Prado-Prado, F.J.; de la Vega, O.M.; Uriarte, E.; Ubeira, F.M.; Chou, K.C.; Gonzalez-Diaz, H. Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Bioorg. Med. Chem., 2009, 17, 569-575.
92. Kubinyi, H. Quantitative structure-activity relationships (QSAR) and molecular modelling in cancer research. J. Cancer Res. Clin. Oncol., 1990, 116(6), 529-537.
93. Prado-Prado, F.J.; Borges, F.; Perez-Montoto, L.G.; Gonzalez-Diaz, H. Multi-target spectral moment: QSAR for antifungal drugs vs. different fungi species. Eur. J. Med. Chem., 2009, 44(10),4051-4056
94. Estrada, E. On the topological sub-structural molecular design (TOSS-MODE) in QSPR/QSAR and drug design research. SAR QSAR Environ. Res., 2000, 11(1), 55-73.
95. Mosier, P.D.; Jurs, P.C. QSAR/QSPR studies using probabilistic neural networks and generalized regression neural networks. J. Chem. Inf. Comput. Sci., 2002, 42(6), 1460-1470.
96. Lombardi, G.; Gramegna, G.; Cavanna, C.; Michelone, G. Fluconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against yeasts isolated from AIDS patients. Microbiologica, 1990, 13(3), 201-206.
97. Fernandez, M.; Caballero, J.; Tundidor-Camba, A. Linear and nonlinear QSAR study of N-hydroxy-2-[(phenylsulfonyl)amino]acetamide derivatives as matrix metalloproteinase inhibitors. Bioorg. Med. Chem., 2006, 14(12), 4137-4150.